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SUPPLEMENTARY INFORMATION 1 
ATIQ – further information 2 
The Asthma Treatment Intrusiveness Questionnaire (ATIQ) scale was adapted from a scale originally 3 
developed by Professor Horne to assess patients’ perceptions of the intrusiveness of antiretroviral 4 
therapies (HAART; the HAART intrusiveness scale).1 This scale assesses convenience and the degree 5 
to which the regimen is perceived by the patient to interfere with daily living, social life, etc. The 6 
HAART intrusiveness scale has been applied to study differential effects of once- vs. twice-daily 7 
antiretroviral regimens2 and might be usefully applied to identify patients who are most likely to 8 
benefit from once-daily treatments. 9 
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Supplementary Table S1. Asthma medications, reported by participants at the time of survey 20 
Asthma medication n (%) 
Salbutamol 406 (40.2) 
Beclometasone 212 (21.0) 
Salmeterol plus fluticasone 209 (20.7) 
Salbutamol plus ipratropium 169 (16.7) 
Formoterol plus budesonide 166 (16.4) 
Fluticasone 135 (13.4) 
Budesonide 131 (13.0) 
Montelukast 123 (12.2) 
Terbutaline 107 (10.6) 
Formoterol plus beclometasone 96 (9.5) 
Ipratroprium bromide 83 (8.2) 
Salmeterol 64 (6.3) 
Sodium cromoglycate 58 (5.7) 
Ciclesonide 52 (5.0) 
Zafirlukast 44 (4.4) 
Omalizumab 43 (4.3) 
Formoterol 41 (4.1) 
Beclometasone plus salbutamol 37 (3.7) 
Theophylline 36 (3.6) 
Nedocromil sodium 32 (3.2) 
Fenoterol plus ipratropium bromide 27 (2.7) 
Ketotifen 19 (1.9) 
Fenspiride 19 (1.9) 
Doxofylline 19 (1.9) 
Mepiphylline 18 (1.8) 
Flunisolide 14 (1.4) 
Cromoglicic acid 10 (1.0) 
Bombuterol 4 (0.4) 
Bamifylline 3 (0.3) 
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Supplementary Table S2. Goodness-of-fit statistics for structural equation model predicting 23 
adherence, healthcare seeking and asthma control 24 
Goodness of fit statistic Model value Target value if fit perfect Adequate fit 
GFI 0.622 1.0 >0.90 
AGFI 0.597 1.0 >0.90 
PGFI 0.583 1.0 >0.90 
NFI 0.467 1.0 >0.95 
RFI 0.467 1.0 >0.95 
RMSEA 0.108 0.08 0.10 
Hoelter’s index 85 - >200 
Abbreviations: AGFI, adjusted goodness of fit index; GFI, goodness of fit index; NFI, normed fit index; 25 





Supplementary Table S3. Goodness-of-fit statistics for structural equation model predicting 29 
preference for once- vs. twice-daily asthma medication 30 
Goodness of fit statistic Model value Target value if fit perfect Adequate fit 
GFI 0.769 1.0 >0.90 
AGFI 0.745 1.0 >0.90 
PGFI 0.695 1.0 >0.90 
NFI 0.388 1.0 >0.95 
RFI 0.366 1.0 >0.95 
RMSEA 0.115 0.08 0.10 
Hoelter’s index 79 - >200 
Abbreviations: AGFI, adjusted goodness of fit index; GFI, goodness of fit index; NFI, normed fit index; 31 
PGFI, parsimony goodness of fit index; RFI, relative fit index; RMSEA, root mean square error of 32 
approximation. 33 
  34 
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Supplementary Table S4. BMQ questionnaire subscales used to gather participants’ beliefs about 35 
medicines 36 








‘I decide to miss out a dose’ ‘My health, at present, depends on this 
inhaler’ 
‘I sometimes worry about the long-
term effects of this inhaler’ 
‘I forget to take it’ ‘My life would be impossible without 
this inhaler’ 
‘This inhaler gives me unpleasant 
side-effects’ 
‘I alter the dose’ ‘Without this inhaler I would be very ill’ ‘Having to use this inhaler worries 
me’ 
‘I stop taking it for a while’ ‘My health in the future will depend on 
this inhaler’ 
‘This inhaler does more harm than 
good’ 
‘I take it less than instructed’ ‘This inhaler protects me from becoming 
worse’ 












‘I only use it as a reserve, if my 
other treatment doesn’t work’ 
 ‘People who are on preventer 
treatments should stop their 
treatment every now and again’ ‘I only use it when I feel 
breathless’ 
 
‘I only use it when I need it’  ‘This inhaler disrupts my life’ 
‘I try to avoid using it’  ‘I can use as much of this inhaler as I 
need, without having to worry about 
becoming too dependent on it 
(Reverse)’ 
‘I use it before doing 
something which might make 
me breathless’ 
 
Responses were rated on 5-point Likert scales from ‘strongly agree’ to ‘strongly disagree’. 37 
aAdditional asthma-medication specific items.  38 
Abbreviations: BMQ, Beliefs about Medicines Questionnaire; MARS, Medication Adherence Report 39 
Scale (high score = good adherence).   40 
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Supplementary Fig. S1 Full structural equation models identifying (a) predictors of adherence, healthcare seeking and asthma control, and (b) predictors of 




Full structural equation model of associations between adherence barriers, adherence, healthcare seeking, asthma control and asthma severity. All paths 






Full structural equation model of predictors of preference for once- vs. twice-daily treatment. All paths represent standardised regression weights corrected 
by bootstrapping and are significant at P = 0.01. Positive paths are equivalent to an increased preference for twice-daily medication. Negative paths mean 
an increased preference for once-daily medication. S5_2 = presence of high cholesterol.  
ACT, Asthma Control Test™; ATIQ, Asthma Treatment Intrusiveness Questionnaire; BMQ, Beliefs about Medicines Questionnaire; HCS, healthcare seeking; 
MARS, Medication Adherence Report Scale 
 
